NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

FGEN

FibroGen Inc Nasdaq Global Select
$20.32
Open: $19.23 High: $20.4 Low: $18.77 Close: $20.16
Range: 2021-04-19 - 2021-04-20
Volume: 3,801,423
Market: Extended-hours
Powered by Finage Stock APIDelayed data
FGEN
FibroGen Inc 409 Illinois Street San Francisco CA, 94158 http://www.fibrogen.com
FibroGen Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.
  • CEO: Thomas B. Neff
  • Employees: 423
  • Sector: Healthcare
  • Industry: Biotechnology
FGEN News
Latest news about the FGEN
  • Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.

    Radnor, Pennsylvania--(Newsfile Corp. - April 20, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").Investor Deadline Reminder: Investors who purchased or acquired FibroGen securities during ...

    View More →
  • HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Announces Filing of Securities Fraud Class Action

    SAN FRANCISCO, April 20, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Nov. 8, 2019 – Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGEN Contact An Attorney Now: FGEN@hbsslaw.com 844-916-0895 FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen’s presentation of false data of roxadustat to make the anemia drug look safer than it is. Throughout the Class Period, FibroGen touted the prospects of roxadustat. A key selling point for the drug was its purported heart safety as compared to standard of care erythropoietin (EPO) injectable therapies, which cannot be proscribed to a variety of patients at risk of major cardiac events. To support this marketing edge, FibroGen presented data from phase 3 trials purportedly showing roxadustat was safer than EPO, among other at risk populations, in incident dialysis patients. But after the market closed on Apr. 6, 2021, FibroGen stunningly admitted to altering stratification factors to make roxadustat’s hazard ratios indicate lower risk relative to EPO. As a result of the data manipulation, FibroGen CEO Enrique Conterno admitted that the company can no longer say its drug was safer than EPO in incident dialysis patients. In response to this news, several analysts slashed their FibroGen share price targets and reduced their investment recommendations. On this news, the Company’s share price fell over 43%, to close at $19.74 per share on Apr. 7, 2021. Shares continued to fall 5% on Apr. 8, 2021, on heavy volume. “We’re focused on investors’ losses and proving FibroGen senior management intentionally manipulated the safety-related data for its anemia drug,” said Reed Kathrein, the Hagens Berman partner leading the investigation. If you are a FibroGen investor and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman. Whistleblowers: Persons with non-public information regarding FibroGen should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email FGEN@hbsslaw.com. About Hagens BermanHagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw. Contact: Reed Kathrein, 844-916-0895

    View More →
  • FIBROGEN INVESTOR ALERT: Shareholder Lawsuit Filed

    Boston, Massachusetts--(Newsfile Corp. - April 20, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of FibroGen, Inc. (NASDAQ: FGEN). The case is currently in the lead plaintiff stage. Investors who purchased FGEN stock or other securities between November 8, 2019 and April 6, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/FibroGen to submit their information. Investors may ...

    View More →
  • SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 20, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

    View More →
  • FGEN SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.

    NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Fibrogen, Inc., ("Fibrogen" or the "Company") (NASDAQ: FGEN) from November 8, 2019, through April 6, 2021 (the “Class Period”). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934. If you purchased Fibrogen securities, and/or would like to discuss your legal rights and options please visit Fibrogen Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors that:(i) that the Company’s prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of CKD included post-hoc changes to the stratification factors; (ii) that FibroGen’s analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) that, based on these analyses, the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) that, as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) that, as a result of the foregoing, Defendants’ statements about the Company’s business, operations and prospects were materially misleading and/or lacked a reasonable basis. On April 6, 2021, after the market closed, FibroGen issued a press release providing additional information Roxadustat which stated that the “primary cardiovascular safety analyses included post-hoc changes to the stratification factors.” On this news, the Company’s share price fell $14.90, or 43%, to close at $19.74 per share on April 7, 2021, on heavy volume. Shares continued to fall on April 8, 2021, to close at $18.81 per share (a decline of $0.93 per share or 4.7%), on heavy volume. If you wish to serve as lead plaintiff, you must move the Court no later than June 11, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. If you purchased Fibrogen securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/fibrogeninc-fgen-shareholder-class-action-lawsuit-stock-fraud-390/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years. ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information Matthew E. GuarneroBernstein Liebhard LLPhttps://www.bernlieb.com(877) 779-1414MGuarnero@bernlieb.com

    View More →
  • FGEN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Fibrogen, Inc. Shareholders

    New York, New York--(Newsfile Corp. - April 20, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders FibroGen, Inc. (NASDAQ: FGEN).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/fibrogen-inc-loss-submission-form/?id=14895&from=5Affected shareholders purchased shares of FGEN between November 8, 2019 and April 6, 2021Shareholders interested in representing the class of wronged shareholders have until June 11, 2021 to petition the court. Your ability to share in any recovery doesn't require that ...

    View More →
  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

    Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

    View More →
  • SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

    NEW ORLEANS, April 19, 2021 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 - 3/30/2021Lead Plaintiff Motion Deadline: June 8, 2021SECURITIES FRAUDTo learn more, visit https://www.claimsfiler.com/cases/view-amdocs-limited-securities-litigation-1 FibroGen, Inc. (FGEN)Class Period: 11/8/2019 - 4/6/2021Lead Plaintiff Motion Deadline: June 11, 2021SECURITIES FRAUDTo learn more, visit https://www.claimsfiler.com/cases/view-fibrogen-inc-securities-litigation Canaan Inc. (CAN)Class Period: 2/10/2021 - 4/9/2021Lead Plaintiff Motion Deadline: June 14, 2021SECURITIES FRAUDTo learn more, visit https://www.claimsfiler.com/cases/view-canaan-inc-american-depositary-shares-securities-litigation Credit Suisse Group AG (CS)Class Period: 10/29/2020 - 3/31/2021Lead Plaintiff Motion Deadline: June 15, 2021SECURITIES FRAUDTo learn more, visit https://www.claimsfiler.com/cases/view-credit-suisse-group-ag-american-depositary-shares-securities-litigation If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact us toll-free (844) 367-9658 or visit the case links above. If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline. About ClaimsFiler ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations. To learn more about ClaimsFiler, visit www.claimsfiler.com

    View More →
  • SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN

    New York, New York--(Newsfile Corp. - April 19, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of FibroGen, Inc..Shareholders who purchased shares of FGEN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fibrogen-inc-loss-submission-form/?id=14879&from=5CLASS PERIOD : November 8, 2019 to April 6, ...

    View More →
  • FIBROGEN DEADLINE ALERT

    Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 19, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities ...

    View More →
  • FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.

    New York, New York--(Newsfile Corp. - April 19, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=14875&wire=5Allegations against FGEN include that the Company made materially false and/or misleading statements and/or ...

    View More →
  • Rosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN

    New York, New York--(Newsfile Corp. - April 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no ...

    View More →
  • FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders

    New York, New York--(Newsfile Corp. - April 19, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: November 8, 2019 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:http://www.kleinstocklaw.com/pslra-1/fibrogen-inc-loss-submission-form?id=14863&from=5The filed complaint alleges that FibroGen, Inc. made materially false and/or misleading statements and/or failed ...

    View More →
  • Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action Lawsuit

    The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").

    View More →
  • INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 19, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

    View More →
  • Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

    Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) securities between November 8, 2019 and April 6, 2021, inclusive (the "Class Period").

    View More →
  • LAWSUITS FILED AGAINST FGEN, DDD and CAN - Jakubowitz Law Pursues Shareholders Claims

    NEW YORK, NY / ACCESSWIRE / April 19, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.

    View More →
  • LAWSUITS FILED AGAINST CYDY, FGEN and DDD - Jakubowitz Law Pursues Shareholders Claims

    NEW YORK, NY / ACCESSWIRE / April 19, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.

    View More →
  • FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

    Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired FibroGen securities between November 8, 2019 and April 6, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/fgen.

    View More →
  • HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established

    Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now.

    View More →